SAN DIEGO--(BUSINESS WIRE)--Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that Chief Judge Connolly of the U.S. District Court for the District of Delaware entered Final Judgment that Kurin does not infringe Magnolia Medical, Inc.’s patent. The district court proceedings in the patent infringement lawsuit brought by Magnolia in 2019 are now closed..

。2019年由Magnolia提起的专利侵权诉讼中的地区法院诉讼现已结束。。

“We are pleased that the Court has ruled in our favor,” said Bob Rogers, CEO of Kurin, Inc. “This case took five years and during that time Magnolia has loudly proclaimed that they would put Kurin out of business, creating confusion in the marketplace. We took the high road with our customers and, although it took years, we stayed true to our values and prevailed in the end.”.

Kurin，Inc.首席执行官鲍勃·罗杰斯（BobRogers）表示：“我们很高兴法院做出了有利于我们的裁决。这起案件历时五年，在此期间，白玉兰（Magnolia）曾大声宣布，他们将停止Kurin的业务，在市场上制造混乱。我们与客户走上了正道，尽管花了数年时间，但我们坚持了我们的价值观，最终取得了胜利。”。

“Previously, on Dec. 1, 2023, the US Patent and Trademark Office issued a final rejection of the key patent claims that were the cornerstone of this litigation. This is a complete victory for our team, confirming both that the Kurin Lock does not infringe any Magnolia patent and that the asserted patent is invalid.

。

We are pleased to have this distraction behind us and can now continue on our mission of partnering with clinicians to improve clinical and financial outcomes regarding blood culture contaminations.”.

我们很高兴能够摆脱这种分心，现在可以继续与临床医生合作，改善血培养污染的临床和财务结果。”。

Kurin’s revolutionary 510(k) cleared approaches to the contaminated blood culture problem are based on elegantly simple, intuitive designs that require no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C.

库林革命性的510（k）清除污染血培养问题的方法是基于优雅简单、直观的设计，不需要额外的用户步骤。库林在血培养采集过程中被动地排除潜在的污染物。受污染的血培养是一个重大问题，因为大约三分之一的阳性结果是错误的，使这些患者接触不必要的抗生素，延长住院时间，并影响更大的社区健康问题，如抗菌素耐药性和危及生命的C。

diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems..

差异感染。Kurin Lock和Kurin Jet为临床医生提供了解决这些问题所需的工具。。

About Kurin, Inc.

关于Kurin，Inc。

Kurin, Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com..

Kurin，Inc.，一家经认证的少数民族企业（MBE），专注于帮助医疗保健提供者减少受污染血培养的产品的设计、开发、制造、营销和销售。在加利福尼亚州圣地亚哥制造的Kurin已获得FDA 510（k）市场许可。有关库林的更多信息，请访问网站www.Kurin.com。。